Powerfleet, a global AIoT software company, will hold a conference call on November 9, 2026, to discuss its financial results for the second quarter of fiscal year 2027 ending September 30, 2026. The company will release its financial results in a press release before the call, which will include a presentation by management and a Q&A session. This event provides investors insight into Powerfleet's recent performance and strategic direction. The call will be accessible via phone and webcast on the company's investor website.
Powerfleet's upcoming Q2 fiscal 2027 conference call is the subject here, providing context for readers. For those following the Technology sector, 94 out of 150 US stocks traded on Pluang rose while 53 fell. Notable movers include CRDO at USD 152.37 with an 8.82% increase, GRAB at USD 3.11 up 8.74%, and AXTI at USD 52.12 rising 8.13%, as of Nov 04, 2026 03:41 WIB.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
